Tags

Type your tag names separated by a space and hit enter

Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis.
Clin Chem Lab Med. 2005; 43(4):357-60.CC

Abstract

Antibody titer against malondialdehyde (MDA)-modified low-density lipoprotein (LDL) has been found to be associated with atherosclerosis, but it has not been established whether it would detect subjects with coronary artery disease (CAD). In the present study, receiver-operating characteristic (ROC) analysis was used to compare the diagnostic accuracy of the antibody titer against MDA-modified LDL and high-density lipoprotein (HDL) and LDL cholesterol levels in discrimination between subjects with (n = 51) and without (n = 35) angiographically verified 3-vessel CAD. As a result, the antibody titer against MDA-modified LDL was lower in subjects with CAD compared with subjects without CAD (p < 0.0001). The area under the ROC plot was 0.822 (95% CI, 0.727 to 0.918) for the antibody titer and 0.769 (95% CI, 0.661 to 0.876) for the HDL cholesterol concentration. Both the antibody titer and the plasma HDL cholesterol level were more accurate markers of CAD than the LDL cholesterol level. As a conclusion, our results indicate that the antibody titer against MDA-modified LDL discriminates between subjects with widespread CAD and those without CAD similarly as the HDL cholesterol concentration. Moreover, the antibody titer against MDA-modified LDL is inversely correlated with the risk of severe CAD.

Authors+Show Affiliations

Laboratory of Atherosclerosis Genetics, Tampere University Hospital, Centre for Laboratory Medicine and Department of Clinical Chemistry, University of Tampere, Finland. riikka.rontu@uta.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15899649

Citation

Rontu, Riikka, et al. "Antibody Titer Against Malondialdehyde-modified LDL Compares With HDL Cholesterol Concentration in Identifying Angiographically Verified Coronary Artery Disease. Comparison of Tests By ROC Analysis." Clinical Chemistry and Laboratory Medicine, vol. 43, no. 4, 2005, pp. 357-60.
Rontu R, Metso S, Jaakkola O, et al. Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis. Clin Chem Lab Med. 2005;43(4):357-60.
Rontu, R., Metso, S., Jaakkola, O., Nikkilä, M., Jokela, H., & Lehtimäki, T. (2005). Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis. Clinical Chemistry and Laboratory Medicine, 43(4), 357-60.
Rontu R, et al. Antibody Titer Against Malondialdehyde-modified LDL Compares With HDL Cholesterol Concentration in Identifying Angiographically Verified Coronary Artery Disease. Comparison of Tests By ROC Analysis. Clin Chem Lab Med. 2005;43(4):357-60. PubMed PMID: 15899649.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis. AU - Rontu,Riikka, AU - Metso,Saara, AU - Jaakkola,Olli, AU - Nikkilä,Matti, AU - Jokela,Hannu, AU - Lehtimäki,Terho, PY - 2005/5/19/pubmed PY - 2005/9/2/medline PY - 2005/5/19/entrez SP - 357 EP - 60 JF - Clinical chemistry and laboratory medicine JO - Clin. Chem. Lab. Med. VL - 43 IS - 4 N2 - Antibody titer against malondialdehyde (MDA)-modified low-density lipoprotein (LDL) has been found to be associated with atherosclerosis, but it has not been established whether it would detect subjects with coronary artery disease (CAD). In the present study, receiver-operating characteristic (ROC) analysis was used to compare the diagnostic accuracy of the antibody titer against MDA-modified LDL and high-density lipoprotein (HDL) and LDL cholesterol levels in discrimination between subjects with (n = 51) and without (n = 35) angiographically verified 3-vessel CAD. As a result, the antibody titer against MDA-modified LDL was lower in subjects with CAD compared with subjects without CAD (p < 0.0001). The area under the ROC plot was 0.822 (95% CI, 0.727 to 0.918) for the antibody titer and 0.769 (95% CI, 0.661 to 0.876) for the HDL cholesterol concentration. Both the antibody titer and the plasma HDL cholesterol level were more accurate markers of CAD than the LDL cholesterol level. As a conclusion, our results indicate that the antibody titer against MDA-modified LDL discriminates between subjects with widespread CAD and those without CAD similarly as the HDL cholesterol concentration. Moreover, the antibody titer against MDA-modified LDL is inversely correlated with the risk of severe CAD. SN - 1434-6621 UR - https://www.unboundmedicine.com/medline/citation/15899649/Antibody_titer_against_malondialdehyde_modified_LDL_compares_with_HDL_cholesterol_concentration_in_identifying_angiographically_verified_coronary_artery_disease__Comparison_of_tests_by_ROC_analysis_ L2 - https://www.degruyter.com/doi/10.1515/CCLM.2005.065 DB - PRIME DP - Unbound Medicine ER -